Dr. Corinne Epperly has been appointed U.S. chief operating officer, VBL Therapeutics. Dr. Epperly is an oncology expert with industry background in drug development, strategy, commercialization and operations. She will have responsibility in forming VBL’s marketing strategy and commercialization plan for its Phase III candidate VB-111 and will work with VBL’s leadership team to advance corporate strategy and U.S. activities. Dr. Epperly will report to VBL’s chief executive officer, Dr. Dror Harats.

“We are delighted to welcome Dr. Epperly to VBL’s senior leadership team,” said Dr. Harats. “She brings strong experience in oncology drug development and commercialization, particularly in glioblastoma. Among other achievements, she has led multibillion-dollar global transactions and complex international negotiations, as well as corporate strategy and commercial execution. Her impressive skills and industry track record will be valuable assets to VBL as we continue to advance our lead therapeutic candidate, VB-111, in multiple oncology indications.”

Dr. Epperly joins the company from Bristol-Myers Squibb, where she held diverse roles spanning marketing, M&A, strategic operations and medical strategy. Most recently she was involved in leading the preparation for the commercial launches of OPDIVO (nivolumab) in both hepatocellular carcinoma and in glioblastoma. While at BMS she led U.S. immuno-oncology safety management, advancing the safety strategy with oncology stakeholders. Dr. Epperly also served as the Global Mergers & Acquisitions Lead in the Strategic Transactions Group at BMS.